LRMR — Larimar Therapeutics Share News
0.000.00%
Last trade - 00:00- $313.73m
- $157.46m
Larimar Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Larimar Therapeutics Reports Q3 2022 Results
Larimar Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Larimar Therapeutics Announces Issuance Of U.S. Patent Providing Composition Of Matter Protection For CTI-1601
Guggenheim initiates coverage of Larimar Therapeutics at 'buy'
U.S. STOCKS ON THE MOVE-Rumble Inc, Virios Therapeutics, KnowBe4
U.S. STOCKS ON THE MOVE-Take-Two, Virios Therapeutics, Netflix
Larimar rises after William Blair upgrades rating to 'outperform'
U.S. STOCKS ON THE MOVE-Nucor, Larimar Therapeutics, gold miners
Larimar Therapeutics rises after FDA partially lifts clinical hold on rare disease drug
Brief: Larimar Therapeutics Announces $70 Million Underwritten Offering
Brief: Larimar Therapeutics Announces FDA Clearance To Initiate The 25 Mg Cohort Of A Phase 2 Dose Exploration Trial Of Cti-1601 In Friedreich’S Ataxia Patients
U.S. STOCKS ON THE MOVE-Forza X1, GlobalFoundries, Avient
U.S. STOCKS ON THE MOVE-AirSculpt, Honest, Acer Therapeutics
U.S. STOCKS ON THE MOVE- Larimar, WeTrade, Joby Aviation
Larimar surges on plan to resolve clinical hold on rare disease drug
Larimar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Larimar Therapeutics Provides Updates On CTI-1601 Clinical Program
Larimar Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview